Cisplatin, used against several tumors, should be administered only in patients for whom there are no alternative treatments until the market normalizes in a few weeks. The incidents with the supply of cisplatin began in February, when Pfizer notified the AEMPS that the drug Cisplatino Pharmacia 1 mg/ml concentrate for solution for infusion suffered a quality problem at its global manufacturing plant.

This problem, now resolved, has meant a delay in the release of batches for distribution. The Agency has made these decisions together with the Spanish Society of Medical Oncology (SEOM) and the Spanish societies of Hematology and Hemotherapy (SEHH), and Hospital Pharmacy (SEFH). It is an active ingredient indicated in metastatic or advanced lung cancer and in testicular, bladder, ovarian, and head and neck squamous cell cancer, also metastatic, advanced or metastatic. The available doses are distributed through the Medication Service in Special Situations.